Genotyping Assay Market Size, Share & Trends by Product & Services (Kits, Instruments, Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (Pharma & Biotech Companies, Diagnostic Labs) & Region - Global Forecast to 2029
Report Code: BT 3397 Jun, 2024, by marketsandmarkets.com
The global genotyping assay market is expected to grow from $19.4 billion in 2024 to $37.1 billion by 2029, at a CAGR of 13.8%. This growth is driven by advancements in DNA sequencing technology, rising prevalence of genetic disorders, and increased application in personalized medicine and drug development. Key market drivers include the growing use of genotyping in drug discovery and development, while high instrument costs act as a restraint. Opportunities lie in expanding applications in animal genetics and agricultural biotechnology. North America dominates the market, and major players include Thermo Fisher Scientific, Illumina, and QIAGEN. The market is segmented by product & services, technology, applications, end-users, and regions. Reagents & kits and PCR technologies lead in market share, with pharmacogenomics being the largest application segment.
Genotyping Assay Market Trends
To know about the assumptions considered for the study, Request for Free Sample Report
Genotyping Assay Market Dynamics
Driver: Growing importance and use of genotyping in drug discovery and development
With the increased availability of investments and government funding for conducting genomics-based research, several CROs and academic researchers have started gene-based research studies to develop innovative disease management strategies with the help of genotyping. The increasing demand for pharmacogenomics is highlighting the potential for growth in genotyping tests. The drug discovery and development market has increasingly adopted these tests for assessing drug efficacy and safety and finding new biomarker assays for drug profile assessment, toxicity prediction, risk assessment, dosing determination, treatment decision-making, and drug response evaluation. Thus, the growing importance and use of genotyping in the drug discovery and development process is expected to drive market growth.
Restraint: High manufacturing, installation, and maintenance costs of genotyping instruments
Genotyping instruments are equipped with advanced features and functionalities, making them highly-priced. Pharmaceutical companies and research laboratories require a number of such systems, creating the need for significant investments in procuring multiple high-cost genotyping instruments. For instance, the Genome Institute at Washington University is reported to have 30 sequencing instruments (Illumina HiSeq 2000s) costing an estimated USD 750,000 each. Academic research laboratories also find it difficult to afford such systems due to budget constraints. Maintenance costs and several other indirect expenses, such as sample and labor costs, also result in an overall increase in the total cost of ownership of these instruments. As a result, the installation/expansion of advanced research facilities such as NGS technology is hampered in academic and research institutes in emerging countries across Asia, the Middle East, and Africa.
Opportunity: Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology
Although the identification of human genetic disorders and drug discovery are the major application areas of genomics, its application in agriculture, veterinary sciences, and forensics, among other fields, has increased in recent years to identify quality and produce desirable genetic traits, increase the productivity and quality of food, ensure the safety of food, improve the health of animals, diagnose genetic disorders, search for disease prevention and treatment options, and improve sustainability. The application of genomics in forensic studies has improved drastically with the advent of NGS. Earlier, DNA analysis was used for fingerprint profiling, which is now being replaced by genomic recreation of the complete genome
Challenge: Lack of adequate data management in genomics research
Large amounts of data are produced by genotyping research, both quantitative and qualitative. Previously, this data was manually saved, which posed a significant problem because gigabytes of data could be generated in a matter of hours. By developing databases to store genotyping data, technological improvements have made data storage more automated. For technologists, comprehending the complete potential of these datasets presents an additional challenge.
Genotyping assay Ecosystem/Market Map
In 2023, Reagents & Kits segment accounted for the highest CAGR of the genotyping assay industry
The genotyping assay market is mainly divided into four segments based on product and service: bioinformatics, instruments, reagents and kits, and GENOTYPING ASSAY services. In 2023, the Genotyping assay's greatest share was held by the reagents & kits category. The significant portion of this market can be ascribed to the availability of a broad variety of reagents, the rising demand for reagents as a result of the global increase in GENOTYPING ASSAY test volumes, and the comparatively lower initial investment needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities.
In 2023, The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay industry, by technology, during the forecast period
Polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides) are the main technological segments of the genotyping assay market. In 2023, the PCR segment held the greatest proportion of the market for GENOTYPING ASSAY technology. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.
In 2023, Pharmacogenomics segment accounted for the highest share of the industry
Pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications make up the majority of the market's application segments. In terms of GENOTYPING ASSAY applications, the pharmacogenomics sector held the biggest share of the genotyping assay market in 2023. The need to lower the overall cost of medication development for pharmaceutical companies and the growing demand for pharmacogenomics to research adverse drug reactions (ADRs) in clinical trials are the primary drivers of growth in this market. The pharmacogenomics genetyping test is predicted to grow due to various factors, including the rising need for personalized medication, the rise in hereditary and life-threatening disorders, and ongoing research on effective and alternative drug delivery techniques.
In 2023, Biopharmaceutical & pharmaceutical companies segment accounted for the highest share of the genotyping assay industry
The genotyping assay market is mainly divided into diagnostic laboratories, academic & research institutes, biopharmaceutical & pharmaceutical firms, and other end users based on end user classification. In 2023, the biopharmaceutical & pharmaceutical companies segment held the greatest share of the end-user market for GENOTYPING ASSAY. The significant market share of this industry may be ascribed to the growing need for pharmacogenomics in the drug research and discovery process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process. Furthermore, growing partnerships and funding for pharmacogenomics research further support the expansion of this market sector for GENOTYPING ASSAY.
North America is the largest regional market for genotyping assay industry
The global genotyping assay market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America held the most market share for genotyping assay worldwide in 2023. The expansion of the North American market may be ascribed to the relationship between rising population and rising levels of research.
To know about the assumptions considered for the study, download the pdf brochure
The major players in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), Eurofins Scientific (Luxembourg). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.
Scope of the Genotyping Assay Industry
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$19.4 billion |
|
Projected Revenue by 2029 |
$37.1 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 13.8% |
|
Market Driver |
Growing importance and use of genotyping in drug discovery and development |
|
Market Opportunity |
Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology |
This report categorizes the genotyping assay market to forecast revenue and analyze trends in each of the following submarkets:
By Product and Services
- Reagents & Kits
- Genotyping Services
-
Instruments
- Sequencers and Amplifiers
- Analyzers
-
Bioinformatics
- Software
- Services
By Technology
-
Polymerase Chain Reaction
- Real-Time Polymerase Chain Reaction
- Digital Polymerase Chain Reaction
- Microarrays
-
Sequencing
- Next-Generation Sequencing
- Pyrosequencing
- Sanger Sequencing
-
Capillary Electrophoresis
- Amplified Fragment Length Polymorphism
- Restriction Fragment Length Polymorphism
- Single-Strand Confirmation Polymorphism
- Matrix-assisted Laser Desorption/Ionization-time of Flight
- Other Technologies
By Application
- Pharmacogenomics
- Diagnostics and Personalized Medicine
- Animal Genetics
- Agricultural Biotechnology
- Other Applications
By End User
- Pharmaceutical & Biopharmaceutical Companies
- Diagnostic Laboratories
- Academic & Research Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East Africa
- GCC Countries
Recent Developments of the genotyping assay industry:
- In February 2023, Agilent launched an On-deck thermal cycler that provides thermal cycling as part of an automated workflow for NGS, end-point PCR, and cell-based applications..
- In May 2023, Illumina Connected Insights, a new cloud-based software that enables tertiary analysis for clinical next-generation sequencing data. This software will help with genomic profiling (CGP) for advanced tumors, along with whole-genome sequencing for rare diseases and other advanced applications.
- In January 2023, QIAGEN launched the QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kits.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global genotyping assay market?
The global genotyping assay market boasts a total revenue value of $37.1 billion by 2029.
What is the estimated growth rate (CAGR) of the global genotyping assay market?
The global genotyping assay market has an estimated compound annual growth rate (CAGR) of 13.8% and a revenue size in the region of $19.4 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 GENOTYPING ASSAY MARKET OVERVIEW
4.2 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
4.3 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029
4.4 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029
4.5 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029
4.6 GENOTYPING ASSAY MARKET: REGIONAL GROWTH OPPORTUNITIES (2024–2029)
5 MARKET OVERVIEW (Page No. - 64)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological advancements and reduced prices of DNA sequencing
5.2.1.2 Increasing incidence of genetic diseases and rising use of personalized medicines
5.2.1.3 Growing importance and use of genotyping in drug discovery and development
5.2.1.4 Increasing demand for bioinformatics solutions in data analysis
5.2.2 RESTRAINTS
5.2.2.1 High manufacturing, installation, and maintenance costs of genotyping instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing use of genomics in animal genetics and agricultural biotechnology
5.2.4 CHALLENGES
5.2.4.1 Lack of adequate data management in genomics research
5.2.4.2 Dearth of trained healthcare personnel for genomic sequencing data analysis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
5.3.2 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
5.4 PATENT ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.9.2 KEY BUYING CRITERIA
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.5 Middle East
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
5.11.2 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Polymerase chain reaction
5.12.1.2 Next-generation sequencing
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 CRISPR-based perturbational
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Single-cell RNA sequencing
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15 CASE STUDY ANALYSIS
5.15.1 DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN
5.16 INVESTMENT & FUNDING SCENARIO
6 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE (Page No. - 90)
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET
6.3 GENOTYPING SERVICES
6.3.1 RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH
6.4 INSTRUMENTS
6.4.1 SEQUENCERS & AMPLIFIERS
6.4.1.1 Decreasing cost of DNA sequencing procedures to aid market growth
6.4.2 ANALYZERS
6.4.2.1 Technological advancements in high-throughput analyzers to support market growth
6.5 BIOINFORMATICS
6.5.1 SOFTWARE
6.5.1.1 High volume of sequencing and microarray tests to augment segment growth
6.5.2 SERVICES
6.5.2.1 Increasing public-private funding to support segment growth
7 GENOTYPING ASSAY MARKET, BY TECHNOLOGY (Page No. - 114)
7.1 INTRODUCTION
7.2 POLYMERASE CHAIN REACTION
7.2.1 REAL-TIME POLYMERASE CHAIN REACTION
7.2.1.1 Continuous automation of laboratory techniques to propel market growth
7.2.2 DIGITAL POLYMERASE CHAIN REACTION
7.2.2.1 High cost of instruments and lack of knowledge among end users to limit market growth
7.3 MICROARRAYS
7.3.1 HIGH DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
7.4 SEQUENCING
7.4.1 NEXT-GENERATION SEQUENCING
7.4.1.1 Higher speed and better accuracy to fuel segment growth
7.4.2 PYROSEQUENCING
7.4.2.1 Growing need for genotyping difficult assays with accurate results to augment growth
7.4.3 SANGER SEQUENCING
7.4.3.1 Increasing use in small-scale experiments to boost segment growth
7.5 CAPILLARY ELECTROPHORESIS
7.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM
7.5.1.1 Increasing use in determining genetic differences to drive segment
7.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM
7.5.2.1 Rising demand in forensics and agricultural institutions to support market growth
7.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM
7.5.3.1 Increasing applications in virology to boost segment growth
7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
7.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH
7.7 OTHER TECHNOLOGIES
8 GENOTYPING ASSAY MARKET, BY APPLICATION (Page No. - 162)
8.1 INTRODUCTION
8.2 PHARMACOGENOMICS
8.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET
8.3 DIAGNOSTICS & PERSONALIZED MEDICINES
8.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH
8.4 ANIMAL GENETICS
8.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH
8.5 AGRICULTURAL BIOTECHNOLOGY
8.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH
8.6 OTHER APPLICATIONS
9 GENOTYPING ASSAY MARKET, BY END USER (Page No. - 178)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
9.3 DIAGNOSTIC LABORATORIES
9.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
9.5 OTHER END USERS
10 GENOTYPING ASSAY MARKET, BY REGION (Page No. - 192)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 US to dominate North American genotyping assay market during forecast period
10.2.2 CANADA
10.2.2.1 Increasing government initiatives and funding for genomics research to drive market
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth
10.3.2 UK
10.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth
10.3.3 FRANCE
10.3.3.1 Rising government investments in genomics to boost market growth
10.3.4 ITALY
10.3.4.1 Favorable funding scenario in genomics research to support market growth
10.3.5 SPAIN
10.3.5.1 Increased R&D funding by government to spur market growth
10.3.6 REST OF EUROPE
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth
10.4.2 JAPAN
10.4.2.1 Launch of technologically advanced sequencing platforms to drive market
10.4.3 INDIA
10.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth
10.4.4 REST OF ASIA PACIFIC
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Establishment of manufacturing facilities by key players to propel market growth
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements and increased government support to boost market growth
10.5.3 REST OF LATIN AMERICA
10.5.4 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.7 GCC COUNTRIES
10.7.1 IMPROVED HEALTHCARE INFRASTRUCTURE AND RISE IN LIFESTYLE-RELATED DISEASES TO FUEL MARKET GROWTH
10.7.2 GCC COUNTRIES: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 282)
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Product & service footprint
11.5.5.3 Technology footprint
11.5.5.4 Application footprint
11.5.5.5 Region footprint
11.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.8.1 THERMO FISHER SCIENTIFIC INC.
11.8.2 AGILENT TECHNOLOGIES, INC.
11.8.3 QIAGEN
11.8.4 ILLUMINA, INC.
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS
11.9.2 DEALS
12 COMPANY PROFILES (Page No. - 296)
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC.
12.1.1.1 Business overview
12.1.1.2 Products/Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches and approvals
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 ILLUMINA, INC.
12.1.2.1 Business overview
12.1.2.2 Products/Services/Solutions offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches
12.1.2.3.2 Deals
12.1.2.3.3 Expansions
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 DANAHER CORPORATION
12.1.3.1 Business overview
12.1.3.2 Products/Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches
12.1.3.3.2 Deals
12.1.3.4 MnM View
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 QIAGEN
12.1.4.1 Business overview
12.1.4.2 Products/Services/Solutions offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches and developments
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 EUROFINS SCIENTIFIC
12.1.5.1 Business overview
12.1.5.2 Products/Services/Solutions offered
12.1.5.3 Recent developments
12.1.5.3.1 Product and service launches
12.1.5.3.2 Deals
12.1.5.4 MnM View
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 F. HOFFMANN-LA ROCHE LTD.
12.1.6.1 Business overview
12.1.6.2 Products/Services/Solutions offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches
12.1.6.3.2 Deals
12.1.7 AGILENT TECHNOLOGIES, INC.
12.1.7.1 Business overview
12.1.7.2 Products/Services/Solutions offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches and approvals
12.1.8 BIO-RAD LABORATORIES, INC.
12.1.8.1 Business overview
12.1.8.2 Products/Services/Solutions offered
12.1.9 MERCK KGAA
12.1.9.1 Business overview
12.1.9.2 Products/Services/Solutions offered
12.1.10 STANDARD BIOTOOLS
12.1.10.1 Business overview
12.1.10.2 Products/Services/Solutions offered
12.2 OTHER PLAYERS
12.2.1 REVVITY
12.2.2 PACBIO
12.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY)
12.2.4 OXFORD NANOPORE TECHNOLOGIES PLC
12.2.5 GENEWIZ, INC.
12.2.6 TAKARA BIO INC.
12.2.7 BGI GROUP
12.2.8 PROMEGA CORPORATION
12.2.9 NOVOGENE CO., LTD.
12.2.10 GENSCRIPT
12.2.11 NEW ENGLAND BIOLABS
12.2.12 PARAGON GENOMICS, INC.
12.2.13 NEOGENOMICS LABORATORIES
12.2.14 TECAN TRADING AG
12.2.15 GENOTYPIC TECHNOLOGY PVT. LTD.
13 APPENDIX (Page No. - 364)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES(444 TABLES)
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 GENOTYPING ASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 GENOTYPING ASSAY MARKET: RISK ASSESSMENT
TABLE 4 PRICING ANALYSIS TREND FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
TABLE 5 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
TABLE 6 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET
TABLE 7 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM
TABLE 8 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES
TABLE 14 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
TABLE 15 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
TABLE 16 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025
TABLE 17 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 18 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 24 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 34 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2022–2029, (USD MILLION)
TABLE 45 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 50 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 51 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 61 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION
TABLE 62 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 63 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS
TABLE 69 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 70 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS
TABLE 75 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 KEY MICROARRAYS
TABLE 81 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 87 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 KEY NEXT-GENERATION SEQUENCING PRODUCTS
TABLE 93 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 KEY PYROSEQUENCING PRODUCTS
TABLE 99 PYROSEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 KEY SANGER SEQUENCING PRODUCTS
TABLE 105 SANGER SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 106 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 112 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 117 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS
TABLE 122 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 123 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS
TABLE 128 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS
TABLE 134 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 OTHER GENOTYPING TECHNOLOGIES
TABLE 140 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 146 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 151 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 156 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 157 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 162 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 166 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 167 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 171 GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 172 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 174 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 175 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 178 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 179 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 188 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 GENOTYPING ASSAY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 202 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 203 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 204 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 206 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 207 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 211 US: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 212 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 213 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 220 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 221 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 223 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 231 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 232 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 239 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 240 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 241 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 248 UK: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 249 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 250 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 257 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 258 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 259 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 266 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 267 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 268 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 275 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 284 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 294 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 295 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 296 CHINA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 CHINA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 CHINA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 299 CHINA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 CHINA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 301 CHINA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 CHINA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 303 CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 304 JAPAN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 305 JAPAN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 306 JAPAN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 JAPAN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 308 JAPAN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 JAPAN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 310 JAPAN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 311 JAPAN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 312 JAPAN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 313 INDIA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 314 INDIA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 INDIA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 INDIA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 317 INDIA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 318 INDIA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 INDIA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 INDIA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 INDIA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 322 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 323 REST OF ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 324 REST OF ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 325 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 326 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 327 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 331 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 332 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 333 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 335 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 336 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 337 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 338 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 340 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 341 BRAZIL: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 342 BRAZIL: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 343 BRAZIL: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 BRAZIL: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 345 BRAZIL: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 346 BRAZIL: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 347 BRAZIL: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 348 BRAZIL: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 349 BRAZIL: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 350 MEXICO: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 351 MEXICO: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 352 MEXICO: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 353 MEXICO: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 354 MEXICO: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 355 MEXICO: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 356 MEXICO: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 357 MEXICO: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 358 MEXICO: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 359 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 360 REST OF LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 361 REST OF LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 362 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 363 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 364 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 365 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 366 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 367 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 368 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 369 MIDDLE EAST & AFRICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 MIDDLE EAST & AFRICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 372 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 375 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 376 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 377 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 378 GCC COUNTRIES: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 GCC COUNTRIES: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 380 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 381 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 383 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 384 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 385 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 386 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
TABLE 387 GENOTYPING ASSAY MARKET: DEGREE OF COMPETITION
TABLE 388 GENOTYPING ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 389 GENOTYPING ASSAY MARKET: TECHNOLOGY FOOTPRINT
TABLE 390 GENOTYPING ASSAY MARKET: APPLICATION FOOTPRINT
TABLE 391 GENOTYPING ASSAY MARKET: REGION FOOTPRINT
TABLE 392 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 393 GENOTYPING ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 394 GENOTYPING ASSAY MARKET: PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS, JANUARY 2020–MARCH 2024
TABLE 395 GENOTYPING ASSAY MARKET: DEALS, JANUARY 2020–MARCH 2024
TABLE 396 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 397 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
TABLE 399 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020–MARCH 2024
TABLE 400 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 401 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 402 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 403 ILLUMINA, INC.: DEALS, JANUARY 2020–MARCH 2024
TABLE 404 ILLUMINA, INC.: EXPANSIONS, JANUARY 2020–MARCH 2024
TABLE 405 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 406 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 407 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 408 DANAHER CORPORATION: DEALS, JANUARY 2020–MARCH 2024
TABLE 409 QIAGEN: COMPANY OVERVIEW
TABLE 410 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 411 QIAGEN: PRODUCT LAUNCHES AND DEVELOPMENTS, JANUARY 2020–MARCH 2024
TABLE 412 QIAGEN: DEALS, JANUARY 2020–MARCH 2024
TABLE 413 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 414 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 415 EUROFINS SCIENTIFIC: PRODUCT AND SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 416 EUROFINS SCIENTIFIC: DEALS, JANUARY 2020–MARCH 2024
TABLE 417 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 418 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 419 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 420 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2020–MARCH 2024
TABLE 421 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 422 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
TABLE 424 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 425 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 426 MERCK KGAA: COMPANY OVERVIEW
TABLE 427 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 428 STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 429 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 430 REVVITY: COMPANY OVERVIEW
TABLE 431 PACBIO: COMPANY OVERVIEW
TABLE 432 LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW
TABLE 433 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 434 GENEWIZ, INC.: COMPANY OVERVIEW
TABLE 435 TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 436 BGI GROUP: COMPANY OVERVIEW
TABLE 437 PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 438 NOVOGENE CO., LTD.: COMPANY OVERVIEW
TABLE 439 GENSCRIPT: COMPANY OVERVIEW
TABLE 440 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 441 PARAGON GENOMICS, INC.: COMPANY OVERVIEW
TABLE 442 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
TABLE 443 TECAN TRADING AG: COMPANY OVERVIEW
TABLE 444 GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW
LIST OF FIGURES (59 FIGURES)
FIGURE 1 GENOTYPING ASSAY MARKET: SEGMENTS COVERED
FIGURE 2 GENOTYPING ASSAY MARKET: REGIONS COVERED
FIGURE 3 GENOTYPING ASSAY MARKET: YEARS CONSIDERED
FIGURE 4 GENOTYPING ASSAY MARKET: RESEARCH DESIGN
FIGURE 5 KEY DATA FROM SECONDARY SOURCES
FIGURE 6 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES
FIGURE 7 GENOTYPING ASSAY MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 10 COMPANY REVENUE ESTIMATION APPROACH
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 12 GENOTYPING ASSAY MARKET: TOP-DOWN APPROACH
FIGURE 13 GENOTYPING ASSAY MARKET: DATA TRIANGULATION METHODOLOGY
FIGURE 14 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 20 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 21 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 22 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 23 GENOTYPING ASSAY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
FIGURE 24 TECHNOLOGICAL ADVANCEMENTS AND REDUCED PRICES OF DNA SEQUENCING TO DRIVE MARKET
FIGURE 25 REAGENTS & KITS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 26 POLYMERASE CHAIN REACTION TO POSSESS LARGEST MARKET SHARE BETWEEN 2024 AND 2029
FIGURE 27 PHARMACOGENOMICS TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO COMMAND LARGEST MARKET SHARE FROM 2024 TO 2029
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 30 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 31 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2002–2022
FIGURE 32 PATENT APPLICATIONS FOR GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023
FIGURE 33 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS
FIGURE 34 GENOTYPING ASSAY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 35 GENOTYPING ASSAY MARKET: ECOSYSTEM MAP
FIGURE 36 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 37 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 38 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
FIGURE 39 REVENUE SHIFT IN GENOTYPING ASSAY MARKET
FIGURE 40 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT
FIGURE 41 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2021–2023)
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2023)
FIGURE 44 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 45 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT
FIGURE 46 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 47 EV/EBITDA OF KEY VENDORS
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 49 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 53 QIAGEN: COMPANY SNAPSHOT (2023)
FIGURE 54 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023)
FIGURE 59 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023)
The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the genotyping assay market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Breakdown Of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
F. Hoffmann-La Roche Ltd. (Switzerland) |
Marketing Manager |
|
Thermo Fisher Scientific, Inc. (US) |
Senior Product Manager |
|
QIAGEN N.V. (Netherlands) |
Marketing Manager |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the home healthcare market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the genotyping assay market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global genotyping assay Market Size: Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global genotyping assay Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Genotyping is used to study the differences in the genetic makeup (specific genome variants) of cells, microorganisms, plants, animals, and individuals. These differences in genotypes are determined by studying individual DNA sequences using biological assays and comparing them with other reference sequences. This process has wide applications in the field of life sciences, including animal genetics, diagnostic research, & pharmacogenomics, agricultural biotechnology, and personalized medicine.
Key Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global genotyping assay market by product and services, technology, application, enduser, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall genotyping assay market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries.
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
MarketsandMarkets offers the following customizations for this market report
Country Information
- Additional country-level analysis of the genotyping assay market
Company profiles
- Additional five company profiles of players operating in the genotyping assay market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the genotyping assay market
Generating Response ...
Growth opportunities and latent adjacency in Genotyping Assay Market